J&J joins ‘menin party’ at ASH; GSK to work with Oxford BioTherapeuticsnews2025-12-10T15:34:26+00:00December 10th, 2025|Endpoints News|
#SABCS25: Roche’s breast cancer pill cuts post-surgery disease recurrence risk by 30%news2025-12-10T13:15:32+00:00December 10th, 2025|Endpoints News|
PsiThera gets $47.5M for oral I&I drugs after spinning out from Roivantnews2025-12-10T12:00:41+00:00December 10th, 2025|Endpoints News|
Formation Bio signs deal for TYK2 drug from China’s Lynknews2025-12-10T12:00:15+00:00December 10th, 2025|Endpoints News|
UK lowers new medicine rebate scheme to 14.5% for 2026news2025-12-10T11:49:17+00:00December 10th, 2025|Endpoints News|
D3 Bio raises $108M to take next-gen KRAS G12C drug into Phase 3news2025-12-10T11:40:43+00:00December 10th, 2025|Endpoints News|
BlossomHill gets another $84M for macrocyclic approach to EGFRnews2025-12-10T11:30:14+00:00December 10th, 2025|Endpoints News|
FDA is taking another look at safety of approved RSV antibodiesnews2025-12-09T21:02:59+00:00December 9th, 2025|Endpoints News|
Eli Lilly earmarks $6B for GLP-1 pill factory in Alabamanews2025-12-09T20:30:05+00:00December 9th, 2025|Endpoints News|
FDA’s probe of Covid-19 vaccines expands into adultsnews2025-12-09T19:22:12+00:00December 9th, 2025|Endpoints News|
